Zelluna ASA (ZLNA)

Currency in NOK
22.50
+0.50(+2.27%)
Real-time Data·
ZLNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.0022.50
52 wk Range
8.2035.80
Key Statistics
Prev. Close
22
Open
22.4
Day's Range
22-22.5
52 wk Range
8.2-35.8
Volume
65.46K
Average Volume (3m)
75.86K
1-Year Change
55.3653%
Book Value / Share
3.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZLNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Zelluna ASA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Zelluna ASA Earnings Call Summary for Q2/2026

  • Zelluna dosed first patient in ZI-MA4-1 trial; independent safety committee deemed initial data favorable and recommended continued enrollment.
  • Q2 operating loss narrowed to NOK 20M from prior year as payroll and overhead costs declined; H1 2026 operating loss totaled NOK 40M.
  • Company ended Q2 with NOK 86M cash, sufficient to fund operations into Q3 2027; raised NOK 58M via private placement at NOK 18.50/share.
  • Dose-escalation phase expected to complete in H1 2027 before expansion; updated clinical data to be presented at ESMO 2026 conference.
  • Shares fell 3.57% to $21.6 post-update as investors await efficacy data; stock up 62% YTD but remains below 52-week high of $35.8.
Last Updated: 2026/08/20, 09:56
Read Full Transcript

Earnings

Latest Release
Aug 20, 2026
EPS / Forecast
-0,70 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ZLNA Income Statement

Compare ZLNA to Peers and Sector

Metrics to compare
ZLNA
Peers
Sector
Relationship
P/E Ratio
−5.6x−3.4x−0.4x
PEG Ratio
−0.10−0.070.00
Price/Book
6.1x2.3x2.6x
Price / LTM Sales
-7.6x3.1x
Upside (Analyst Target)
-307.7%46.0%
Fair Value Upside
Unlock9.2%5.3%Unlock

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6,75K0,02%148,41K
Other Institutional Investors
20,12M68,42%442,74M
Public Companies & Retail Investors
9,28M31,56%204,21M
Total
29,41M100,00%647,1M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RADFORSK8,95%2 631 85557 901
Greenwich Holdings Ltd.8,53%2 507 83255 172

FAQ

What Is the Zelluna (ZLNA) Stock Price Today?

The Zelluna stock price today is 22,50 NOK.

What Stock Exchange Does Zelluna Trade On?

Zelluna is listed and trades on the Oslo Stock Exchange.

What Is the Stock Symbol for Zelluna?

The stock symbol for Zelluna is "ZLNA."

What Is the Zelluna Market Cap?

As of today, Zelluna market cap is 647,10M NOK.

What Is Zelluna's Earnings Per Share (TTM)?

The Zelluna EPS (TTM) is -4,80.

When Is the Next Zelluna Earnings Date?

Zelluna will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is ZLNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Zelluna Stock Split?

Zelluna has split 0 times.

How Many Employees Does Zelluna Have?

Zelluna has 15 employees.

What is the current trading status of Zelluna (ZLNA)?

As of Aug 27, 2026, Zelluna (ZLNA) is trading at a price of 22,50 NOK, with a previous close of 22,00 NOK. The stock has fluctuated within a day range of 22,00 NOK to 22,50 NOK, while its 52-week range spans from 8,20 NOK to 35,80 NOK.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.